Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 15, 2025 09:26 ET | Source: Er-Kim Pharmaceuticals

Er-Kim Announces Exclusive Distribution Agreement with Polaris Pharmaceuticals to Commercialize Pegargiminase (ADZODI) for Malignant Pleural Mesothelioma (MPM) in Multiple EMEA Markets

Er-Kim signs distribution agreement with Polaris Pharmaceuticals to commercialize Pegargiminase (ADZODI) across 36 markets in the EMEA region
January 14, 2025 13:30 ET | Source: Er-Kim

Er-Kim ogłasza zawarcie wyłącznej umowy dystrybucyjnej z MEDICE Health Family dla Vafseo® w Europie Środkowej i Wschodniej

WARSZAWA, Polska, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Er-Kim, międzynarodowa firma specjalizująca się w komercjalizacji nowych terapii dla firm farmaceutycznych i biofarmaceutycznych, ogłosiła dziś...
January 14, 2025 08:00 ET | Source: Er-Kim

Er-Kim Announces Exclusive Distribution Agreement with the MEDICE Health Family For Vafseo® in Central & Eastern Europe

Er-Kim's partnership will support access of an alternative treatment to improve the lives of people impacted by anemia caused by chronic kidney disease
December 10, 2024 07:00 ET | Source: Er-Kim

Er-Kim Extends Exclusive Distribution Agreement with Ascendis Pharma A/S to Expand Commercialization of Its Endocrinology Portfolio to Eurasian Markets

Er-Kim broadens drug distribution for novel rare endocrinology disease therapies in CEE and Eurasian markets
October 15, 2024 07:00 ET | Source: Er-Kim

Er-Kim CEO Cem Zorlular Recognized as a Patient Champion on the 2024 PharmaVoice 100

Cem Zorlular, CEO of Er-Kim recognized as a patient champion in this year's PharmaVoice100
March 05, 2024 09:00 ET | Source: Er-Kim

Er-Kim Selected to Join the World Economic Forum’s New Champions Community

ATHENS, Greece, March 05, 2024 (GLOBE NEWSWIRE) -- Er-Kim, a pharmaceutical company specializing in the commercialization of novel therapies in international markets, announced today it has been...
January 08, 2024 18:01 ET | Source: Er-Kim

Er-Kim Announces Exclusive Distribution Agreement with Ascendis Pharma A/S to Commercialize 3 Endocrinology Disease Treatments Across Central & Eastern Europe and Turkey

Er-Kim is appointed as the exclusive Ascendis A/S endocrinology distributor across Central & Eastern Europe and Turkey
November 24, 2023 08:00 ET | Source: Er-Kim Pharmaceuticals

Er-Kim Pharmaceuticals Supports Worldwide Prevention of Antimicrobial Resistance (AMR)

Er-Kim Pharmaceuticals joins the industry to collaborate on the prevention of antimicrobial resistance (AMR) in support of World AMR Awareness Week